Presentation

IRLAB is a clinical-stage Swedish company that develops novel treatments for Parkinson’s disease and other CNS disorders. The company’s most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Ph2b and are designed to treat some of the most difficult complications related to Parkinson’s disease. IRLAB also runs several preclinical programs with IRL942 and IRL757 currently in development towards Ph1 studies. The company discovers and generates all drug candidates through its systems biology-based Integrative Screening Process (ISP).

Recent highlights
In March, IRLAB nominated a new drug candidate, IRL757, for the treatment of apathy in neurological diseases and has initiated studies in preparations of Ph1. In April, IRLAB announced the acquisition of know-how linked to development of innovative chemistry and patents in the P003 project for Parkinson’s disease from Per Lindberg Consulting AB, which is expected to further strengthen IRLAB’s P003 project and patent applications related to the project. In July, IRLAB announced that the ongoing Ph2b/3 study has been expanded to include 154 patients aiming to provide strong data supporting the design of the pivotal Ph3 program and subsequent marketing authorisation applications. The last patient is expected to complete treatment in late fall 2022.

Outlook
One of IRLAB’s key strategic goals is to widen its portfolio and is currently investing fully in two preclinical programs, IRL942 and IRL757. The company also aims to report top-line results from the ongoing Ph2b/3 study in H2 2022.